Benefits of step-by-step debulking microwave ablation for huge unresectable hepatocellular carcinoma patients after transcatheter arterial chemoembolization refractoriness

References

• Akinyemiju T, Abera S, Ahmed M, Global Burden of Disease Liver Cancer C, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: Results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683–1691.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953.
   PubMed Web of Science ®Google Scholar
• Zhou L, Rui JA, Wang SB, et al. Prognostic factors of solitary large hepatocellular carcinoma: the importance of differentiation grade. Eur J Surg Oncol. 2011;37(6):521–525.
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–1255.
   PubMed Web of Science ®Google Scholar
• Lo GH. Updated management of hepatocellular carcinoma. Hepatology. 2011;54(3):1113.
   PubMed Web of Science ®Google Scholar
• Hwang S, Lee Y-J, Kim K-H, et al. The impact of tumor size on long-term survival outcomes after resection of solitary hepatocellular carcinoma: single-institution experience with 2558 patients. J Gastrointest Surg. 2015;19(7):1281–1290.
   PubMed Web of Science ®Google Scholar
• Shrager B, Jibara GA, Tabrizian P, et al. Resection of large hepatocellular carcinoma (≥ 10 cm): a unique Western perspective. J Surg Oncol. 2013;107(2):111–117.
   PubMed Web of Science ®Google Scholar
• Kluger MD, Salceda JA, Laurent A, et al. Liver resection for hepatocellular carcinoma in 313 Western patients: tumor biology and underlying liver rather than tumor size drive prognosis. J Hepatol. 2015;62(5):1131–1140.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429–442.
   PubMed Web of Science ®Google Scholar
• Xue T, Le F, Chen R, et al. Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study. Med Oncol. 2015;32(3):64.
   PubMed Web of Science ®Google Scholar
• Min YW, Lee JH, Gwak GY, et al. Long-term survival after surgical resection for huge hepatocellular carcinoma: comparison with transarterial chemoembolization after propensity score matching. J Gastroenterol Hepatol. 2014;29(5):1043–1048.
   PubMed Web of Science ®Google Scholar
• Lencioni R. Chemoembolization for hepatocellular CarcinomaSeminars. Oncology. 2012;39(4):503–509.
   Web of Science ®Google Scholar
• Farinati F, Giacomin A, Vanin V, et al. TACE treatment in hepatocellular carcinoma: what should we do now? J Hepatol. 2012;57(1):221–222.
   PubMed Web of Science ®Google Scholar
• Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011;37(3):212–220.
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The L, European Organisation For R, Treatment Of C EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.
   PubMed Web of Science ®Google Scholar
• Kudo M, Matsui O, Izumi N, Liver Cancer Study Group of Japan, et al. JSH Consensus-Based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan. Liver Cancer. 2014;3(3-4):458–468.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390.
   PubMed Web of Science ®Google Scholar
• Brunocilla PR, Brunello F, Carucci P, et al. Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Med Oncol. 2013;30(1):345.
   PubMed Web of Science ®Google Scholar
• Galle PR, Tovoli F, Foerster F, et al. The treatment of intermediate stage tumours beyond TACE: from surgery to systemic therapy. J Hepatol. 2017;67(1):173–183.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Solbiati L, Brace CL, Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria – a 10-year update. Radiology. 2014;273(1):241–260.
   PubMed Web of Science ®Google Scholar
• Lau WY, Leung TW, Yu SC, et al. Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg. 2003;237(2):171–179.
   PubMed Web of Science ®Google Scholar
• Ke S, Gao J, Kong J, et al. Repeated radiofrequency ablation combined with ablated lesion elimination and transarterial chemoembolization improves the outcome of solitary huge hepatocellular carcinomas 10 cm or larger. Medicine. 2016;95(16):e3393.
   PubMed Web of Science ®Google Scholar
• Ogasawara S, Chiba T, Ooka Y, et al. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology. 2014;87(6):330–341.
   PubMed Web of Science ®Google Scholar
• Arizumi T, Ueshima K, Minami T, et al. Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma. Liver Cancer. 2015;4(4):253–262.
   PubMed Web of Science ®Google Scholar
• Miyayama S, Kikuchi Y, Yoshida M, et al. Outcomes of conventional transarterial chemoembolization for hepatocellular carcinoma ≥ 10 cm. Hepatol Res. 2019;49(7):787–798.
   PubMed Web of Science ®Google Scholar
• Wei CY, Chen PC, Chau GY, et al. Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma. Ann Transl Med. 2020;8(5):238–238.
   PubMed Web of Science ®Google Scholar
• Kido C, Sasaki T, Kaneko M. Angiography of primary liver cancer. Am J Roentgenol Radium Ther Nucl Med. 1971;113(1):70–81.
   PubMedGoogle Scholar
• Sugano S, Miyoshi K, Suzuki T, et al. Intrahepatic arteriovenous shunting due to hepatocellular carcinoma and cirrhosis, and its change by transcatheter arterial embolization. Am J Gastroenterol. 1994;89:184–188.
   PubMed Web of Science ®Google Scholar
• Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol. 2012;56(6):1330–1335.
   PubMed Web of Science ®Google Scholar
• Hidaka T, Anai H, Sakaguchi H, et al. Efficacy of combined bland embolization and chemoembolization for huge (≥ 10 cm) hepatocellular carcinoma. Minim Invasive Ther Allied Technol. 2021;30(4):221–228.
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005;11(9):1086–1092.
   PubMed Web of Science ®Google Scholar
• Zen C, Zen Y, Mitry RR, et al. Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation. Liver Transpl. 2011;17(8):943–954.
   PubMed Web of Science ®Google Scholar
• Wang B, Xu H, Gao ZQ, et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol. 2008;49(5):523–529.
   PubMed Web of Science ®Google Scholar
• Miyayama S, Matsui O, Zen Y, et al. Portal blood supply to locally progressed hepatocellular carcinoma after transcatheter arterial chemoembolization: Observation on CT during arterial portography. Hepatol Res. 2011;41(9):853–866.
   PubMed Web of Science ®Google Scholar
• Fang Q, Xie QS, Chen JM, et al. Long-term outcomes after hepatectomy of huge hepatocellular carcinoma: a single-center experience in China. Hepatobiliary Pancreat Dis Int. 2019;18(6):532–537.
   PubMed Web of Science ®Google Scholar
• Nault JC, Sutter O, Nahon P, et al. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. J Hepatol. 2018;68(4):783–797.
   PubMed Web of Science ®Google Scholar
• Zhao J, Wu J, He M, et al. Comparison of transcatheter arterial chemoembolization combined with radiofrequency ablation or microwave ablation for the treatment of unresectable hepatocellular carcinoma: a systemic review and meta-analysis. Int J Hyperthermia. 2020;37(1):624–633.
   PubMed Web of Science ®Google Scholar
• Zheng L, Li HL, Guo CY, et al. Comparison of the efficacy and prognostic factors of transarterial chemoembolization plus microwave ablation versus transarterial chemoembolization alone in patients with a large solitary or multinodular hepatocellular carcinomas. Korean J Radiol. 2018;19(2):237–246.
   PubMed Web of Science ®Google Scholar
• Stadlbauer V, Lang-Olip I, Leber B, et al. Immunohistochemical and radiological characterization of wound healing in porcine liver after radiofrequency ablation. Histol Histopathol. 2016;31(1):115–129.
   PubMed Web of Science ®Google Scholar